Palatin Technologies

$0.6935
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0675 (-8.81%) Today
-$0.0056 (-0.80%) As of 10:32 PM UTC after-hours

Why Robinhood?

You can buy or sell PTN and other stocks, options, and ETFs commission-free!

About PTN

Palatin Technologies, Inc., also called Palatin Technologies, is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ. The listed name for PTN is Palatin Technologies, Inc.

CEO
Carl Spana
Employees
20
Headquarters
Cranbury, New Jersey
Founded
1986
Market Cap
159.19M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
8.40M
High Today
$0.75
Low Today
$0.66
Open Price
$0.75
Volume
5.33M
52 Week High
$1.30
52 Week Low
$0.355

PTN Earnings

-$0.04
$0.05
$0.14
$0.23
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected May 11, After Hours

You May Also Like

ASAQ=
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure